LV Unloading Does not Reduce Infarct Size in Anterior MI: STEMI DTU Trial
Key Points: Even after timely reperfusion, heart failure (HF) complicates a high…
Two-Lead CRT-DX System Without Atrial Pacing Non-Inferior to Conventional Three-Lead CRT-D: Results from the CRT-NEXT Trial
Key Points: Cardiac resynchronization therapy (CRT) has become a cornerstone treatment for…
AI-Based ECG Screening for Structural Heart Disease Demonstrates Moderate Performance in a Community Setting: Results from the PREVUE-VALVE Study
Key Points: With an aging population, the incidence and prevalence of valvular…
First-in-Human Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy Safe and Dose-Dependent PKP2 Protein Restoration: HEROIC-PKP2 Trial
Key Points: Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiac disorder characterized…
ATTRibute-CM Open-Label Extension: Acoramidis for ATTR-CM Provides Sustained Reductions in Mortality Through 54 months
Key Points: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by…
Dig-RHD: Digoxin Reduces Heart Failure Events in Patients with Rheumatic Heart Disease
Key Points: Rheumatic heart disease (RHD) results from heart valve damage caused…
TRISCEND II Two-Year Follow-Up: Transcatheter Tricuspid Valve Replacement Demonstrates Durable TR Elimination and Quality-of-Life Improvement at Two Years
Key Points: Severe tricuspid regurgitation is common and is associated with reduced…
Beta-Blocker Discontinuation Non-inferior to Continuation in Stable Patients After MI: SMART-DECISION Trial
Key Points • In the randomized SMART-DECISION trial conducted in Korea, discontinuation…
OCT+CMR Combined Identify Underlying Cause in Majority of MINOCA Cases, No Sex Differences in Mechanisms: The HARP Trial
Key Points Myocardial infarction with no obstructive coronary arteries accounts for approximately…
Prehospital Heparin Improves Coronary Patency in STEMI Without Excess Bleeding: UFH-STEMI Trial
Key Points Unfractionated heparin is standard anticoagulation during primary PCI for STEMI,…
NT-proBNP-Based Screening Identifies Undiagnosed Heart Failure in Patients with Diabetes: The TARTAN-HF Trial
Key Points Heart failure affects patients with diabetes at disproportionately high rates,…
Tirzepatide Reduces Cardiorenal Outcomes vs Dulaglutide in Patients with Diabetes and CV Disease: SURPASS-CVOT Post Hoc Analysis
Key Points Tirzepatide targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors,…
IVUS- guided PCI Reduces One-Year Target Vessel Failure vs Angiography -guided PCI in Complex Bifurcation PCI: DKCRUSH VIII Trial
Key Points Intravascular imaging has been increasingly recognized as a cornerstone of…
IVUS-guided PCI was Not Associated with Lower Risk of Target-Vessel Failure vs Angiography-guided PCI alone in Complex High-Risk PCI: IVUS-CHIP Trial
Key Points Intravascular ultrasound guidance during percutaneous coronary intervention has been associated…
Oral NLRP3 Inhibitor, Parunoflast, Reduces Inflammation Alone and in Combination with Semaglutide in Phase 2a Trial
Key Points Inflammation plays a central role in atherosclerosis, with activation of…
LX2006 Gene Therapy Shows Early Signals of Cardiac Benefit in Friedreich Ataxia Cardiomyopathy
Key Points Friedreich ataxia (FA) is a rare, progressive, autosomal recessive disorder…
Next-generation Cardiac Myosin Inhibitor- BHB/HRS-1893- Promising in Reducing LVOT Gradient in Obstructive HCM: Phase 2 Results
Key Points Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by dynamic left ventricular…
Anti-fibrotic Therapy After TAVI Improved Myocardial Fibrosis Regression and Quality of Life: Reduce-MFA Trial
Key Points Myocardial fibrosis is a key driver of adverse cardiac remodeling…
NPR1 Agonist XXB750 Fails to Improve Cardiac Biomarkers and Increases Heart Failure Events in Phase 2 Trial
Key Points In an Investigative Horizons session at the American College of…
CORALreef Add-on Shows Oral Enlicitide Lowered LDL-C More Than Guideline Recommended Oral Non-Statin Comparators
Key Points • In the phase 3 CORALreef Add-on trial, oral enlicitide…